Business Wire

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly

22.5.2026 14:45:00 EEST | Business Wire | Press release

Share

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/

Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve.

Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the same time, access to prevention remains unequal, with underserved communities often facing the greatest barriers to early screening and timely care, as well as reliable health information. The Future Health Challenge focused on solutions designed to detect health risks sooner, monitor population-level data, and support faster decision-making by health authorities.

Five finalist teams presented their solutions to an international audience spanning global health, philanthropy, investment, technology and life sciences, with the judging team awarding prizes to the following teams:

  • ThinkMD, Australia
    USD 200,000, Winner
    ThinkMD equips frontline health workers with mobile clinical decision-support tools that improve triage, treatment, and referral, while turning routine care encounters into real-time population health signals. The platform is already used by more than 9,000 frontline workers across 885 facilities, with the platform’s ability to act as an early warning system demonstrated through previously detected symptom patterns preceding a cholera outbreak in Zambia.

  • Vector Control Innovations, United States
    USD 50,000, Distinguished Finalist
    VectorCam uses AI-enabled mosquito surveillance to detect changing vector risks earlier, helping health systems target interventions before outbreaks escalate. Field evaluations of VectorCam’s impact have shown clear improvements in both efficiency and data quality, with evaluations showing data completeness increasing from around 60% to over 90%.

  • Huna, Brazil
    USD 50,000, Distinguished Finalist
    Huna applies AI to routine blood test data to identify people at elevated cancer risk earlier and guide them into appropriate screening and care pathways. In Brazil, its pilots have screened more than 500,000 patients, and across all deployments to date, hundreds of cancer cases have been detected, many of which would likely have been found later when treatment is more complex and expensive.

Delivered in collaboration with MIT Solve, the Future Health Challenge is part of Future Health’s year-round programme of activities designed to identify and champion high-potential talent globally, connecting innovators with funding, partnerships and pathways to scale solutions that advance longer, healthier lives.

Dr. Jackie Rabec, Co-Founder of ThinkMD, said: “We are thrilled to be the recipients of this award, and we are excited to be able to use it to scale our impact. Our next stage of growth will be expanding in priority markets across Nigeria, Rwanda, Uganda and Somalia, validating our next generation multimodal conversational interface and furthering our self-care product to deliver health intelligence into the hands of citizens.”

Dr. Asma Al Mannaei, Executive Director of the Health and Life Sciences Sector at the Department of Health – Abu Dhabi said “Too often, health systems only detect risk once it has become illness, when treatment is more complex and outcomes are worse. Solutions from the Future Health Challenge are designed to identify risk earlier and support more timely decisions at a population level. The priority now is testing and scaling what works in real-world settings.”

Hala Hanna, Executive Director of MIT Solve, said: “The solutions emerging from this Challenge reflect both the urgency and the opportunity facing health systems globally. By bringing innovators together with policymakers, funders and implementers through platforms such as Future Health, we can help accelerate solutions that are locally grounded and capable of delivering impact at scale.”

MIT Solve has more than a decade of experience in delivering global innovation challenges across health, climate, learning and economic prosperity. To date, MIT Solve has mobilised over USD 80 million in funding for innovators worldwide, with supported solutions reaching more than 370 million lives.

The Challenge forms part of Future Health’s purpose to identify and support innovations that improve health outcomes. Beyond prize funding, participating teams will be connected to partners, investors and health authorities to support the next phase of development and adoption.

Representatives from finalist, semi-finalist and selected Honourable Mention teams will also be invited to showcase their innovations at the Abu Dhabi Future Health Summit, taking place from 20 to 22 October 2026.

Future Health continues to advance a year-round programme across longevity and precision medicine, intelligent health and AI, health system resilience and sustainability, and investment in life sciences, to empower better health worldwide. The platform will continue to introduce new opportunities for global collaboration and discovery of impactful solutions throughout the year.

For more information about the Future Health Challenge and upcoming programme milestones, visit www.futurehealthinitiative.ae

View source version on businesswire.com: https://www.businesswire.com/news/home/20260522587414/en/

Contacts

For media inquiries, please contact media@futurehealthinitiative.ae

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye